- Home
- LU vs ANIP Comparison
LU vs ANIP Comparison
Compare LU & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- ANIP
- Stock Information
- Founded
- LU 2005
- ANIP 2001
- Country
- LU China
- ANIP United States
- Employees
- LU N/A
- ANIP N/A
- Industry
- LU Finance: Consumer Services
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- ANIP Health Care
- Exchange
- LU Nasdaq
- ANIP Nasdaq
- Market Cap
- LU 1.4B
- ANIP 1.3B
- IPO Year
- LU 2020
- ANIP N/A
- Fundamental
- Price
- LU $2.32
- ANIP $56.58
- Analyst Decision
- LU Hold
- ANIP Buy
- Analyst Count
- LU 3
- ANIP 6
- Target Price
- LU $3.58
- ANIP $76.80
- AVG Volume (30 Days)
- LU 2.4M
- ANIP 278.1K
- Earning Date
- LU 10-21-2024
- ANIP 11-08-2024
- Dividend Yield
- LU 6.75%
- ANIP N/A
- EPS Growth
- LU N/A
- ANIP N/A
- EPS
- LU N/A
- ANIP N/A
- Revenue
- LU $4,671,260,668.00
- ANIP $555,456,000.00
- Revenue This Year
- LU N/A
- ANIP $23.69
- Revenue Next Year
- LU $1.48
- ANIP $18.95
- P/E Ratio
- LU N/A
- ANIP N/A
- Revenue Growth
- LU N/A
- ANIP 23.60
- 52 Week Low
- LU $2.00
- ANIP $48.20
- 52 Week High
- LU $4.94
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- LU 33.54
- ANIP 42.32
- Support Level
- LU $2.28
- ANIP $57.80
- Resistance Level
- LU $2.89
- ANIP $63.23
- Average True Range (ATR)
- LU 0.12
- ANIP 2.43
- MACD
- LU -0.04
- ANIP -0.05
- Stochastic Oscillator
- LU 5.74
- ANIP 13.41
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.